IM Cannabis · Nasdaq: IMCC
IM Cannabis
IM Cannabis Corp. is now primarily an Israeli medical-cannabis operator after selling its European-focused holding structure in September 2026. Its common shares trade on Nasdaq under IMCC; the company reported that Nasdaq closed its prior minimum-bid-price deficiency on September 23. The previously supplied Tel Aviv listing identity remains unverified, so this review relies only on the confirmed Nasdaq security.
The June 2026 balance sheet shows why the equity remains speculative. IM Cannabis reported C$1.617 million of cash, C$16.304 million of current assets and C$29.366 million of current liabilities, producing a C$13.062 million working-capital deficit. Six-month cash used in operations was C$1.339 million and capital spending was C$0.006 million, making operating cash flow less capex negative C$1.345 million. Six-month revenue was C$16.268 million, down about 35% year over year, with management citing delayed German shipments, weaker Israeli activity and cash constraints. The statements were unaudited and carried substantial going-concern doubt.
Two later transactions resolved important factual gaps but did not repair the investment case. A 655,000-share registered direct offering closed September 24 at US$2.00 per share for US$1.310 million gross. The October 7 prospectus reported 1,647,494 common shares outstanding, exactly equal to the prior 992,494 shares plus the new issue; the offering represented 39.76% of that post-offering count. Net proceeds and current cash were not disclosed.
On September 29, IM Cannabis completed the related-party sale of IMC Holdings and the European operations while retaining the Israeli business. Consideration included a previously paid C$3.000 million advance and the buyer’s assumption of specified IMC Holdings liabilities capped at C$9.400 million, excluding direct liabilities of the target subsidiaries. Management estimated roughly C$3 million of equity improvement, but final accounting, retained guarantees and current liquidity remain unresolved.
Dilution is the central risk. The October prospectus registers up to 2,799,276 resale shares and says full conversion or exercise of covered instruments could raise common shares to 4,408,146. That is 2,760,652 potential incremental shares, or 167.57% above the October 7 count. Registration does not itself mean issuance, and ownership limits affect timing, but the ceiling makes a per-share valuation premature. Variable-price settlement notes, outstanding warrants and conversions after October 7 also prevent a reliable current diluted denominator.
CIN status: NotRated. Rating, price target, reference quote and upside are null. A current opinion requires post-disposal Israeli-only financial statements, final closing entries, current cash and debt, a fully diluted security registry, evidence of sustainable operating cash flow and a compatible dated market quote. Until those items are available, the paper is a fact-checked initial review rather than a completed valuation underwrite.
Original sources: SEC-filed June financial statements, offering-close Form 6-K, disposal-close Form 6-K, and October prospectus.